LONGHORN VACCINES AND DIAGNOSTICS


Associated tags: Diagnosis, Temperature, Mycobacterium tuberculosis, MTM, Vaccine, RNA, DNA, SARS-CoV-2, Infection, TB, FDA, Health, Longhorn, Public, Biotechnology, Pharmaceutical, Infectious Diseases, Science, Epitope, Peptide, MD, Research, Virus, Veterinary, COVID-19

Locations: BOSTON, IA, EUROPE, SPAIN, UNITED STATES, NORTH AMERICA, MARYLAND, MAB

Longhorn Vaccines and Diagnostics Presents New Data on its Best-In-Class Infectious Disease Vaccine and Antibody Portfolio at ECCMID 2024

Retrieved on: 
Saturday, April 27, 2024
Science, Other Science, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Other Health, Infection, Immunoglobulin G, PGN, University, Public, Hook effect, Coronavirus, Mouse, Gram-positive bacteria, Risk, ECCMID, MTB, Vaccine, Human, GA4, Immunodeficiency, Mycobacterium tuberculosis, Virus, Pig, Immune system, Antibody, Tuberculosis, Bird

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented positive data from three key studies of its infectious disease franchise at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented positive data from three key studies of its infectious disease franchise at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024.
  • ECCMID is taking place online and in-person in Barcelona, Spain from April 27-30, 2024.
  • Longhorn’s vaccine and antibody product candidates focus on rapidly mutating viruses that include influenza, coronavirus, and antimicrobial resistant pathogens.
  • “We are very excited to present the first data from our universal influenza vaccine in pigs,” said Jeff Fischer, President Longhorn Vaccines and Diagnostics.

Longhorn Vaccines and Diagnostics to Present Data on LHNVD-105, a Universal Vaccine Candidate, at ECCMID 2024

Retrieved on: 
Thursday, April 11, 2024
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, Neuraminidase, Infection, Public, University, Gram-positive bacteria, Mycobacterium tuberculosis, Epidemiology, Abstract, ECCMID, Epitope, Vaccine

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present three abstracts at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present three abstracts at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024.
  • ECCMID will take place online and in-person in Barcelona, Spain, from April 27-30, 2024.
  • The first two abstracts will detail data on LHNVD-105, an adjuvanted composite peptide universal influenza vaccine, and the monoclonal antibodies it produces.
  • Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)
    Session Title: 10f.

Longhorn Vaccines and Diagnostics Presents at World Vaccine Congress on Advantages of Single Peptide Vaccine for Broad Coverage of Human and Avian Influenza Viruses

Retrieved on: 
Tuesday, April 2, 2024
Health, Infectious Diseases, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Congress, Isotype, Influenza, Group 1, Public, Vaccine, Epitope, ELISA, Mouse, Immunoglobulin G, IND, Immunity, InvivoGen, Poster, Peptide

Results from the poster show that LHNVD-110 generated broadly reactive antibodies to human and highly pathogenic avian influenza viruses while neutralizing seasonal and pandemic influenza strains.

Key Points: 
  • Results from the poster show that LHNVD-110 generated broadly reactive antibodies to human and highly pathogenic avian influenza viruses while neutralizing seasonal and pandemic influenza strains.
  • This data mirrors previous studies with LHNVD-105, a dual peptide vaccines containing the same epitopes.
  • Using a single peptide provides a more cost-effective and easily scalable approach to such a universal influenza vaccine.
  • That is why using peptide-based vaccines with broad strain coverage may offer useful strategies towards preventing influenza, no matter the strain.

Longhorn Vaccines and Diagnostics Presents Targeted Vaccine Approach for Mycobacterium Tuberculosis with LHNVD-301

Retrieved on: 
Wednesday, November 15, 2023
Science, Veterinary, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, Pandemic, Peptide, MTB, Lung, Safety, Peptidoglycan, The Union, Serum, PGN, Immunoglobulin G, Risk, Gram-positive bacteria, Epitope, Staphylococcus aureus, ELISA, Infection, Staphylococcus, Staphylococcus epidermidis, Vaccine, Mycobacterium tuberculosis, Bacillus subtilis, Cell wall, AMR, Conference, Streptococcus, Virus, Antibody, Bacilli, Mycobacterium smegmatis, Tuberculosis, Public, TB, ICR, Bacteria, Longhorn, MD

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today presented new data from an animal study of LHNVD-301, the company’s lead tuberculosis vaccine candidate.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today presented new data from an animal study of LHNVD-301, the company’s lead tuberculosis vaccine candidate.
  • The data showed that a mycobacterium tuberculosis (MTB) vaccine could generate broader protection against other pathogens susceptible to antimicrobial resistance (AMR).
  • LHNVD-301 is an unconjugated, peptide-based vaccine that combines a MTB heat shock protein epitope and a peptidoglycan (PGN) epitope.
  • It represents a novel approach that combats AMR, while targeting tuberculosis by combining multiple epitopes specific to MTB and common to gram-positive bacteria into a peptide vaccine.

Longhorn Vaccines and Diagnostics to Present Data on Mycobacterium Tuberculosis Vaccine Candidate, LHNVD-301, at The Union World Conference on Lung Health 2023

Retrieved on: 
Thursday, November 2, 2023
Science, Other Science, Research, Medical Supplies, General Health, Health, Infectious Diseases, Other Health, The Union, Vaccine, TB, Gram-positive bacteria, International Workshop on Lung Health, Conference, Union, Lung, Public, Mycobacterium tuberculosis, Tuberculosis, Drug resistance, Longhorn, Peptidoglycan

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present new data from an animal study of LHNVD-301, the company’s tuberculosis vaccine candidate, at The Union World Conference on Lung Health 2023.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present new data from an animal study of LHNVD-301, the company’s tuberculosis vaccine candidate, at The Union World Conference on Lung Health 2023.
  • The ePoster will be presented as a part of TBScience 2023, a dedicated event focused on basic and translational tuberculosis (TB) research.
  • LHNVD-301 is an unconjugated, peptide-based vaccine that combines Mycobacterium tuberculosis heat shock protein and Peptidoglycan to generate broad reactive antibodies.
  • ePoster Session Title: TB within the Global AMR fight: preventing drug resistance
    Over the last 53 years, the Union World Conference on Lung Health has presented the latest scientific research in all aspects of lung health, including implementation of evidence-based health policies and decisions.

Longhorn Vaccines and Diagnostics Presents Data Demonstrating Durability of LHNVD-105 Universal Influenza Vaccine in Animal Models at IDWeek 2023

Retrieved on: 
Monday, October 16, 2023
Veterinary, Health, Vaccine, Immunoglobulin G, Public, Antibody, ELISA, Immunity, Pig, Influenza B virus, Epitope, Peptide, Group 1, Infection, Influenza, Isotype, Diagnosis, MD, H1N1, Matrix

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data from an animal study indicating the durability and broad strain coverage of LHNVD-105, the company’s universal influenza vaccine candidate.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data from an animal study indicating the durability and broad strain coverage of LHNVD-105, the company’s universal influenza vaccine candidate.
  • The data was presented at IDWeek 2023, which took place in Boston from October 11-15, 2023.
  • Traditional seasonal influenza vaccines attempt to match circulating influenza strains.
  • Alternate vaccine strategies that target multiple key components of the virus that are conserved across influenza viruses have the potential to combat this issue.

Longhorn Vaccines and Diagnostics Announces Data Showing PrimeStore® Molecular Transport Medium Inactivates High Consequence Animal Viruses

Retrieved on: 
Thursday, October 12, 2023
Veterinary, Health, Food, Vaccine, Pithing, BioRxiv, Doctor of Philosophy, Livestock, Public, Accuracy and precision, Animal, ASF, Safety, Collection, Virus, African swine fever virus, Influenza B virus, Poultry, SARS-CoV-2, Virulent Newcastle disease, Molecular diagnostics, Human, HPAI, Zoonosis, Dicarboxylic acid, Animal husbandry, Longhorn, DVM

Zoonotic diseases are a significant threat to human and animal populations and global food production.

Key Points: 
  • Zoonotic diseases are a significant threat to human and animal populations and global food production.
  • This includes the SARS-CoV-2 global pandemic that has dramatically affected humans and domestic and wild animal species.
  • The study, titled “Inactivation of Highly Transmissible Livestock and Avian Viruses Including Influenza A and Newcastle Disease Virus for Molecular Diagnostics,” found:
    PS-MTM completely inactivates viruses representing highly contagious animal diseases in the presence of species-relevant sample matrices.
  • Add to that the biosafety and biosecurity risks of transporting high consequence disease samples and the typical need to keep samples cold.

Longhorn Vaccines and Diagnostics to Present Durability Data of Universal Influenza Vaccine, LHNVD-105, at IDWeek 2023

Retrieved on: 
Tuesday, October 3, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Vaccine, Infection, Public, Longhorn

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present new data from an animal study that examines the durability and broad strain coverage of LHNVD-105, the company’s universal influenza vaccine candidate, at IDWeek 2023.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present new data from an animal study that examines the durability and broad strain coverage of LHNVD-105, the company’s universal influenza vaccine candidate, at IDWeek 2023.
  • IDWeek will take place in-person in Boston, Massachusetts from October 11-15, 2023.
  • LHNVD-105 is an unconjugated, multi-epitope peptide-based vaccine formulated with the highly potent adjuvant Army Liposome Formulation with QS-21 (ALFQ).
  • The vaccine is in development to mitigate infections of human and avian influenza viruses.

New Study Shows Longhorn Vaccines and Diagnostics’ Universal Influenza Vaccine, LHNVD-105, Generates Broad and Durable Immune Responses in Animal Models

Retrieved on: 
Wednesday, September 27, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Human, Army, Poultry, Comparable, Neuraminidase, Public, HA, NA, Immunity, ID, MD, Epitope, Mouse, Poster, Pig, Virus, Peptide, Vaccine, Longhorn

The study demonstrated that LHNVD-105 generates broad and durable immune responses in mice for several human, avian and swine influenza viruses.

Key Points: 
  • The study demonstrated that LHNVD-105 generates broad and durable immune responses in mice for several human, avian and swine influenza viruses.
  • “The Vaccines study extends these findings to show that the durability of the immune response and breadth of influenza strains the vaccines covers to include human and avian viruses.
  • LHNVD-105 demonstrated broad and durable immune responses to the vaccine peptide epitopes and multiple subtypes of influenza viruses.
  • LHNVD-105 induced durable immunity across human, swine, and avian influenza viruses, including A/H5N1, neutralizing both seasonal and pandemic strains.

Longhorn Vaccines and Diagnostics Presents Data Demonstrating Neutralizing Activity of LHNVD-201 for Covid-19 and Influenza Co-Infections

Retrieved on: 
Monday, September 25, 2023
Health, Infectious Diseases, General Health, Pharmaceutical, Biotechnology, Veterinary, Vaccine, ELISA, SARS-CoV-2, Public, Immunity, RNA, Human coronavirus NL63, Group 1 CD1-restricted T cells, COVID-19, MD, Immunoglobulin G, Antibody, Epitope, Mouse, Isotype, Virus, Peptide, Diagnosis, Longhorn, Matrix

Seasonal infections with influenza and Covid-19 along with co-infections are a new threat in the post-pandemic world.

Key Points: 
  • Seasonal infections with influenza and Covid-19 along with co-infections are a new threat in the post-pandemic world.
  • LHNVD-201 is comprised of highly conserved influenza neuraminidase and Matrix (M1/M2) epitopes, and SARS-CoV-2 spike protein and RNA polymerase epitopes.
  • Isotype-specific IgG titers to Covid-19 and influenza peptides were analyzed by an enzyme-linked immunosorbent assay, known as ELISA.
  • Neutralizing activity was demonstrated against Groups 1 and 2 influenza viruses, HCoV-NL63 and SARS-CoV-2.